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Crohn’s disease (CD) is a chronic inflammatory disorder that can 
affect any part of the gastrointestinal tract (GIT), notably the terminal 
ileum and caecum. The major differential diagnosis of CD in our 
setting in Cape Town, South Africa (SA), is intestinal tuberculosis 
(ITB). Both disorders share overlapping clinical, endoscopic, 
radiographic and histological features, notably the presence of tissue 
granulomas. Coupled with a poor microbiological yield in ITB, 
this makes differentiating these diseases challenging. Traditional 
diagnostic modalities such as acid-fast bacilli (AFB), Mycobacterium 
tuberculosis (MTB) culture, tuberculin skin testing, interferon-
gamma release assays and chest radiographs are often negative in 
ITB.[1] In addition, polymerase chain reaction (PCR) testing of the 
GIT for MTB is not validated in our setting and is not currently 
recommended or approved. Given the very high incidence and 
prevalence of MTB infection in SA, a diagnosis of CD is only made 
once ITB has been excluded. This often requires an empirical trial of 
anti-tuberculosis (anti-TB) therapy.[1,2]
Misdiagnosis leads to delays in initiating effective therapy for CD, 
while the use of potent immunomodulators (IMMs) and biologicals 
in the setting of ITB can have fatal consequences. It is therefore 
important to make an accurate diagnosis at the earliest possible stage.
The differentiation of ITB from CD is particularly problematic in 
patients with non-caseating granulomas, as these suggest a very real 
possibility of ITB.[3] To date, no study has been done in this particular 
subgroup to analyse factors that could aid in this diagnostic dilemma.
Objective
To compare patients with granuloma-positive CD and ITB, to identify 
variables that could aid in differentiating between the two conditions.
Methods
The research protocol was approved by the Ethics Committee of 
the University of Cape Town (ref. no.833/2014). A retrospective 
cohort study (2005 - 2015) was conducted evaluating adult patients 
with granuloma-positive CD or ITB. Subjects were identified from 
a pathology database and information was extracted from patient 
folders and laboratory and radiology records.
The following data were collected at presentation: demographics, 
clinical, biochemical, histological and radiographic variables, and 
HIV status (Tables 1 - 4).
The diagnosis of CD was made on the basis of a combination of 
clinical, radiological, endoscopic and histological features as per 
the European Crohn’s and Colitis Organisation consensus state-
ment.[4]
ITB was diagnosed if any of the following were present: AFB 
positivity on tissue biopsy, positive culture for MTB, and full response 
after completion of anti-TB treatment.
Statistical analysis
The association between all baseline risk factors and the diagnosis of 
CD and ITB was assessed by univariate analysis. Normally distributed 
continuous variables are expressed as means (standard deviations 
(SDs)). Continuous variables that were not normally distributed are 
expressed as medians and interquartile ranges (IQRs). Categorical 
variables were compared using the χ2 test, or Fisher’s exact test 
when appropriate. Variables with p-values <0.05 were further tested 
in a series of logistic multivariate regression models. The most 
parsimonious model was selected. The analysis was performed using 
Stata version 11 (StataCorp, USA).
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Results
Sixty-eight patients with ITB and 48 with CD with granulomas 
were identified. Of those with ITB, 42 (61.8%) had AFB present 
on Ziehl-Neelsen staining and 36 (52.9%) were culture-positive for 
MTB. At presentation (Table 1), patients with ITB were younger 
than those with CD (p=0.03), and more likely to be male (p=0.03) 
and of black ethnicity (p<0.0001). Isolated colonic involvement was 
significantly more common in ITB than in CD (p=0.04). There were 
no significant differences in smoking status, symptom duration or 
perianal disease.
Clinical variables associated with a diagnosis of ITB (Table 2) 
were a history of night sweats (p=0.01) and tachycardia (p<0.0001) 
at presentation. Patients with CD were significantly more likely to 
have extraintestinal manifestations (EIMs) than those with ITB 
(p<0.0001). The commonest EIM in CD was iron deficiency anaemia 
(IDA). The only other two EIMs of note were erythema nodosum 
(n=4 cases) and uveitis (n=2), all in patients with CD. Other 
symptoms such as diarrhoea, abdominal pain and weight loss were 
not significant. Similarly, fever, the presence of an abdominal mass 
on palpation and ascites on clinical examination were not predictive.
Thirty-three percent of patients with ITB had a chest radiograph 
with features of active tuberculosis (TB); this was predictive of 
concurrent ITB (p<0.0001). In contrast, radiographic features 
suggesting past TB were not. Overall, only 62.1% of the cohort 
had undergone cross-sectional imaging at presentation (Table 4). 
Of the radiographic abnormalities reported, only lymph nodes 
>1 cm in size and ascites were predictive of ITB. There were 
no significant differences with regard to the presence of central 
node attenuation, splenic abscesses, inflammatory masses or intra-
abdominal collections.
Thirty-five patients with ITB (51.5%) were HIV-positive, as 
opposed to a single patient in the CD group. HIV positivity was 
significantly associated with a diagnosis of ITB (p<0.0001). The mean 
(SD) CD4+ count in the HIV-positive patients was 269 (250) cells/µL.
ITB was also associated with lower serum albumin (p<0.0001) 
and haemoglobin (p<0.0001) values at presentation than CD, as well 
Table 1. Patient demographics at presentation
CD (N=48) ITB (N=68) p-value
Duration of symptoms before diagnosis (months), median (IQR) 9.5 (4 - 12) 3 (1 - 8) 0.06
Age (years), median (IQR) 28 (19 - 24) 35 (26 - 44) 0.03
Gender (female), n (%) 32 (66.7) 31 (45.6) 0.03
Self-declared ethnicity, n (%) <0.0001
White 7 (14.5) 3 (4.4)
Coloured 36 (75.0) 29 (42.7)
Black 5 (10.4) 35 (51.5)
Asian 0 (0.0) 1 (1.5)
Current smoker, n (%) 23 (47.9) 24 (35.3) 0.11
Site of involvement, n (%) 0.04
Ileum 27/45 (60.0) 28/67 (41.8)
Colon 5/45 (11.1) 17/67 (25.4)
Ileum and colon 10/45(22.2) 10/67 (14.9)
Upper GIT 3/45 (6.7) 5/67 (7.5)
Isolated perianal disease 0/45 (0.0) 7/67 (10.5)
Any perianal disease 11/45 (24.4) 12/67 (17.9) 0.40
Previous TB, n (%) 2/45 (4.4) 11/68 (16.2) 0.11
CD = Crohn’s disease; ITB = intestinal tuberculosis; IQR = interquartile range; GIT = gastrointestinal tract; TB = tuberculosis.
Table 2. Clinical features at presentation
CD (N=48) ITB (N=68) p-value
Night sweats, n (%) 4/45 (8.9) 21/67 (31.3) 0.01
Abdominal cramps, n (%) 39/45 (86.7) 49/67 (73.1) 0.09
Nausea and vomiting, n (%) 26/45 (57.8) 34/60 (56.7) 0.58
Bowel action, n (%) 0.92
Normal 18/45 (40.0) 26/67 (38.8)
Diarrhoea 20/45 (44.4) 32/67 (47.8)
Constipation 7/45 (15.6) 9/67 (13.4)
EIMs, n (%) 17/45 (37.8) 3/67 (4.5) <0.0001
Loss of weight, n (%) 31/45 (68.9 51/67 (76.1) 0.4
Weight loss (kg), median (IQR) 7.5 (5 - 10) 10 (5 - 15) 0.54
Temperature (ºC), median (IQR) 36 (36 - 37) 36.8 (35.6 - 37.9) 0.70 
Pulse rate (bpm), median (IQR) 80 (76 - 90) 100 (80 - 115) 0.001
Pulse rate >100 bpm, n (%) 5/44 (11.4) 35/66 (53.0) <0.0001
Palpable abdominal mass, n (%) 6/45 (13.3) 9/67 (13.4) 0.10
Ascites on examination, n (%) 0/45 (0.0)) 2/64 (3.1) 0.23
CD = Crohn’s disease; ITB = intestinal tuberculosis; EIMs = extraintestinal manifestations; IQR = interquartile range; bpm = beats per minute.
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as higher C-reactive protein (CRP) levels (p=0.04) (Table 3). Ninety 
percent of cases of anaemia in ITB were secondary to anaemia of 
chronic disease. On multivariate analysis, HIV positivity (odds ratio 
(OR) 29.72, 95% confidence interval (CI) 2.15 - 410.96; p=0.01), 
isolated colonic disease (OR 6.17, 95% CI 1.17 - 32.52; p=0.03) and 
the absence of EIMs (OR 0.10, 95% CI 0.01 - 0.65; p=0.02) remained 
significant risk factors for ITB. The presence of these three risk 
factors yielded 93% specificity for the diagnosis of ITB. On receiver 
operating characteristic curve analysis, the area under the curve for a 
model of these three risk factors was 0.88 (Fig. 1).
Discussion
Differentiating ITB from CD is notoriously challenging, as they 
share numerous clinical, endoscopic and radiographic features. Both 
diseases can affect the GIT at any point from the mouth to the anus, 
with a predilection for the ileocaecal region. Both may present with 
perianal disease, intestinal strictures or fistulas, and in addition they 
share many EIMs. Distinguishing ITB from CD in SA is further 
complicated by very high rates of MTB infection. Although most 
cases are pulmonary, extrapulmonary TB can occur, and the GIT is 
commonly affected.[5,6]
Treating undiagnosed ITB with potent immunosuppressive CD 
medications can have potentially fatal consequences, particularly 
the risk of dissemination. If the diagnosis is unclear, common 
practice is therefore to give a trial of anti-TB therapy and assess 
the clinical response.[2] This approach is far from ideal, as it delays 
implementation of appropriate CD medication, which may affect 
long-term outcomes. CD is a progressive and destructive illness 
that evolves over time to be complicated by the development of 
strictures, fistulas or abscesses. Ultimately the majority of patients 
require surgery.[7] Aggressive medical therapy with IMMs such as 
azathioprine or methotrexate and biologicals may alter this natural 
history and improve long-term outcomes.[6] However, to be effective 
these should be introduced early in the disease course, ideally at 
diagnosis, before the development of irreversible complications.[6]
Several studies have analysed factors early in the course of CD 
that may predict future outcomes and identify patients at risk of 
developing complicated CD who would receive greatest benefit 
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Fig. 1. ROC curve analysis for the model including EIMs, HIV and isolated 
colonic disease. The presence of these three risk factors yielded 93% specificity 
for the diagnosis of ITB. On ROC analysis, the AUC for a model of these 
three risk factors was 0.88. (ROC = receiver operating curve; EIMs = 
extraintestinal manifestations; ITB = intestinal tuberculosis; AUC = area 
under the curve.)
Table 3. Laboratory parameters at presentation
CD (N=48) ITB (N=68) p-value
Haemoglobin (g/dL), median (IQR) 11.5 (10.4 - 12.5) 9.7 (8.3 - 11.8) 0.01
Haemoglobin >10 g/dL, n (%) 37/43 (86.1) 29/64 (45.3) <0.0001
Serum albumin (g/L), median (IQR) 39 (35 - 42) 30.5 (23 - 36) 0.91
Serum albumin >30 g/L, n (%) 37/42 (88.1) 22/42 (52.4) <0.0001
Platelet count (× 109/L), median (IQR) 412 (322 - 533) 411 (289 - 507) 0.43
CRP (mg/L), median (IQR) 26 (10 - 65) 75 (30 - 109) 0.04
CD = Crohn’s disease; ITB = intestinal tuberculosis; IQR = interquartile range; CRP = C-reactive protein.
Table 4. Radiographic imaging at presentation
CD (N=48) ITB (N=68) p-value
Features of previous TB on CXR, n (%) 2/45 (4.4) 12/68 (17.7) 0.11
Features of active TB on CXR, n (%) 0/45 (0) 22/68 (32.4) <0.0001
Patients who had cross-sectional imaging, n (%) 26/45 (57.8) 46/66 (69.7) 0.24
Type of imaging, n (%) 0.08 
Ultrasound 6/26 (23.1) 17/46 (36.9)
MRE 4/26 (15.4) 1/46 (2.2)
CT 16/26 (61.5) 28/46 (60.9)
Central areas of low attenuation, n (%) 0/23 (0) 5/34 (14.7) 0.16
An inflammatory mass, n (%) 16/26 (61.5) 26/46 (56.5) 0.54
Ascites, n (%) 0/26 (0) 9/46 (29.6) 0.02
Splenic abscesses, n (%) 0/26 (0) 2/34 (5.9) 0.23
Lymph nodes >1 cm, n (%) 1/26 (3.9) 16/46 (34.8) 0.004
Intra-abdominal collections, n (%) 5/26 (19.2) 8/46 (17.4) 0.79
CD = Crohn’s disease; ITB = intestinal tuberculosis; TB = tuberculosis; CXR = chest X-ray; MRE = magnetic resonance enterography; CT = computed tomography.
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from early, aggressive therapy.[6] One such predictor is the presence 
of tissue granulomas on histological examination. A recent cohort 
study in the Western Cape Province, SA, showed a two-fold increase 
in the risk of developing complicated CD in those with this finding 
at diagnosis.[8]
The differentiation of ITB from CD is even more challenging in 
patients with histological evidence of non-caseating granulomas, as 
this further heightens the suspicion of ITB.[3] Patients with ITB are 
significantly more likely to have non-caseating granulomas than 
those with CD.[1,3] This was highlighted in a recent meta-analysis of 
38 studies differentiating CD from ITB. There were 2 117 cases of 
CD and 1 589 cases of ITB. The authors used the data to construct 
a Bayesian model to predict the probability of ITB v. CD. In this 
analysis, the presence of granulomas was significantly associated with 
a diagnosis of ITB.[3]
Ours is the first study with the objective of identifying factors 
differentiating ITB from CD in exclusively granuloma-positive patients. 
Several factors were identified as being valuable in this regard.
On multivariate analysis, the presence of EIMs at diagnosis 
strongly suggested a diagnosis of CD. This is in concordance with 
reports from several cohort studies, as well as the formerly mentioned 
Bayesian model.[3,9]
The commonest EIM in CD was IDA. This finding is not unex-
pected, as it is the most common systemic complication of CD.[10] 
The other reported EIMs in the CD patients were erythema nodosum 
and uveitis.
Several studies have shown that the presence of perianal disease 
strongly supports a diagnosis of CD. Interestingly, this was not seen 
in our study. In fact, in our cohort all seven cases of isolated perianal 
disease were proven to be TB. It is possible that the prevalence 
of perianal TB is underestimated. A 2009 prospective study from 
our institution evaluated 96 patients with perianal fistulas. TB was 
present in 7.3% of cases, suggesting that this is not an uncommon 
manifestation of TB in our setting.[11]
In our study, significantly more patients with ITB than CD had 
isolated colonic involvement (25.4% v. 11.1%). This is higher than in 
other series, where only 10% of patients demonstrated this finding. [12] 
However, the incidence of colonic involvement was increased in 
immunocompromised patients and in those with HIV.[12] In our 
cohort, 50.1% of patients with isolated colonic involvement were 
HIV-infected. This could explain the high incidence of this location.
Other variables supporting a diagnosis of ITB, such as anaemia, 
hypoalbuminaemia, tachycardia and higher median CRP levels, were 
no longer significant on multivariate analysis. This probably reflects 
their association with systemic toxicity and the inflammatory burden 
seen in HIV-TB co-infection, as they were no longer significant after 
adjusting for HIV status.
Not unexpectedly HIV, infection was shown to be the strongest 
risk factor for ITB. It is well recognised that the burden of TB in SA is 
fuelled by the HIV epidemic, with 7 million South Africans infected 
with the virus.[13] SA is currently home to 22.5% of all individuals 
with TB and HIV co-infection across the globe.[13]
Interestingly, in our study patients with granulomatous ITB-HIV 
co-infection had a mean CD4+ count of 269 cells/µL, suggesting 
that granuloma-positive ITB, which is difficult to differentiate from 
CD, requires a degree of immune competence. This is supported by 
data showing that reductions in CD4+ counts in co-infected persons 
were associated with both poorer granuloma formation and higher 
bacterial load.[14]
Study limitations
Given the retrospective nature of this study, there were some missing 
data points. In addition, there were some disease characteristics that 
were poorly documented, on which availability of more detail would 
have enhanced the analysis. These were the number and morphology 
of granulomas, tuberculin skin testing, the endoscopic mucosal 
appearance, the number of diseased colonic segments, and features 
on routine cross-sectional imaging. These would have been useful 
additional tools, as they have been shown to have good diagnostic 
accuracy in differentiating CD from ITB.[15]
Conclusion
Excluding ITB is essential when considering potent immuno-
suppressive therapies for CD. This study focused on subjects with 
tissue granulomas at diagnosis, as these predict a severe course of 
CD. Several clinical and biochemical factors were identified that will 
aid in making the correct diagnosis, notably HIV infection, which 
was the strongest risk factor for ITB in this study. Isolated colonic 
involvement was also associated with ITB, while EIMs predicted a 
diagnosis of CD. To our knowledge, this is the first study to restrict 
analysis to granuloma-positive patients, the subgroup in which 
differentiating CD from ITB is most challenging. These data will aid 
in ensuring a timely diagnosis and reduce the risk of delayed CD 
treatment, as well as misdiagnosing ITB.
Acknowledgements. None.
Author contributions. GW was responsible for study design, data 
collection, statistical analysis, and preparation of the manuscript. ST 
critiqued and modified the final document.
Funding. None.
Conflicts of interest. None.
1. Epstein D, Watermeyer G, Kirsch R. Review article: The diagnosis and management of Crohn’s disease 
in populations with high-risk rates for tuberculosis. Aliment Pharmacol Ther 2007;25(12):1373-1388. 
https://doi.org/10.1111/j.1365-2036.2007.03332.x
2. Ooi CJ, Hilmi I, Makharia GK, et al. The Asia Pacific Consensus Statements on Crohn’s Disease. Part 
1: definition, diagnosis and epidemiology. J Gastroenterol Hepatol 2015;31(1):45-55. https://doi.
org/10.1111/jgh.12956
3. Limsrivilai J, Shreiner AB, Pongpaibul A, et al. Meta-analytic Bayesian model for differentiating 
intestinal tuberculosis from Crohn’s disease. Am J Gastroenterol 2017;112(3):415-427. https://doi.
org/10.1038/ajg.2016.529
4. Gomollón F, Dignass A, Annes V, et al. 3rd European Evidence-based Consensus on the Diagnosis and 
Management of Crohn’s Disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis 
2017;11(1):3-25. https://doi.org/10.1093/ecco-jcc/jjw168
5. Donoghue HD, Holton J. Intestinal tuberculosis. Curr Opin Infect Dis 2009;22(5):490-496. https://doi.
org/10.1097/QCO.0b013e3283306712
6. Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease. Lancet 2017;389(10080):1741-1755. https://
doi.org/10.1016/S0140-6736(16)31711-1
7. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn’s disease. Gastroenterology 
2006;130(3):650-656. https://doi.org/10.1053/j.gastro.2005.12.019
8. Watermeyer G, Thomson SR. Granulomas at initial diagnosis of Crohn’s disease signals a poor 
outcome. S Afr Med J 2015;105(6):480-483. https://doi.org/10.7196/SAMJ.9093
9. Singh B, Kedia S, Konijeti G, et al. Extraintestinal manifestations of inflammatory bowel disease 
and intestinal tuberculosis: Frequency and relation with disease phenotype. Indian J Gastroenterol 
2015;34(1):43-50. https://doi.org/10.1007/s12664-015-0538-7
10. Filmann N, Rey J, Schneeweiss S, et al. Prevalence of anemia in inflammatory bowel diseases in 
European countries: A systematic review and individual patient data meta-analysis. Inflamm Bowel 
Dis 2014;20(5):936-945. https://doi.org/10.1097/01.MIB.0000442728.74340 
11. Stupart D, Goldberg P, Levy A, et al. Tuberculous anal fistulas-prevalence and clinical features in an 
endemic area. S Afr J Surg 2009;47(4):116-118.
12. Debi U, Ravisankar V, Prasad KK, et al. Abdominal tuberculosis of the gastrointestinal tract: Revisited. 
World J Gastroenterol 2014;20(40):14831-14840. https://doi.org/10.3748/wjg.v20.i40.14831
13. World Health Organization. Global Tuberculosis Report 2016. Geneva: WHO, 2016. www.who.int/tb/
publications/global_report/gtbr2016_annex2.pdf (accessed 6 January 2018).
14. Diedrich CR, O’Hern J, Wilkinson RJ. HIV-1 and the Mycobacterium tuberculosis granuloma: 
A systematic review and meta-analysis. Tuberculosis 2016;98:62-76. https://doi.org/10.1016/j.
tube.2016.02.010
15. Kedia S, Sharma R, Nagi B, et al. Computerized tomography-based predictive model for differentiation 
of Crohn’s disease from intestinal tuberculosis. Indian J Gastroenterol 2015;34(2):135-143. https://doi.
org/10.1007/s12664-015-0550-y
Accepted 12 February 2018.
